<DOC>
	<DOC>NCT02077166</DOC>
	<brief_summary>This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) not eligible for transplant.</brief_summary>
	<brief_title>Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses of lenalidomide may be explored, using the 3+3+3 principle for dose determination. Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible subjects will receive ibrutinib, lenalidomide and rituximab.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Pathologically confirmed relapsed/ refractory DLBCL Must have previously received first line treatment regimen Must be ineligible for high dose therapy/ stem cell transplantation Measurable disease sites on CT scan (&gt;1.5 cm in longest dimension) PT/INR &lt;1.5 x ULN and PTT (aPTT) &lt;1.5 x ULN Men and women â‰¥18 years of age ECOG &lt; 2 Adequate hepatic and renal function Adequate hematologic function Medically apparent central nervous system lymphoma or leptomeningeal disease History of allogeneic stemcell (or other organ) transplantation Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeks Radio or toxinimmunoconjugates within 10 weeks Concurrent enrollment in another therapeutic investigational study or have previously taken ibrutinib and/or lenalidomide.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>DLBCL</keyword>
</DOC>